An Immunohistochemical Panel for Reliable Differentiation of Salivary Duct Carcinoma and Mucoepidermoid Carcinoma

Head and Neck Pathology

Volumn 8, Issue 2, 2014, Pages 133-140

  Butler, Randall T ^a   Spector, Matthew E ^a   Thomas, Dafydd ^a   McDaniel, Andrew S ^a   McHugh, Jonathan B ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Immunohistochemistry; Mucoepidermoid carcinoma; Salivary duct carcinoma

Indexed keywords

TUMOR MARKER;

ADULT; AGED; CARCINOMA, MUCOEPIDERMOID; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PATHOLOGY; SALIVARY GLAND DUCT; SALIVARY GLAND NEOPLASMS; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

ADULT; AGED; CARCINOMA, MUCOEPIDERMOID; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; SALIVARY DUCTS; SALIVARY GLAND NEOPLASMS; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84900831997     PISSN: 1936055X     EISSN: 19360568     Source Type: Journal    
DOI: 10.1007/s12105-013-0493-5     Document Type: Article

References (44)

1. Brandwein-Gensler MS, Skálová A, Nagao T. Salivary duct carcinoma. In: Eveson JW, Reichart P, Sidransky D, Barnes L, editors. World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. Lyon: IARC Press; 2005. p. 236-7.
2. Hosal AS, Fan C, Barnes L, Myers EN. Salivary duct carcinoma. Otolaryngol Head Neck. 2003;129(6): 720-5.
3. Barnes L, Rao U, Krause J, Contis L, Schwartz A, Scalamogna P. Salivary duct carcinoma: part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol. 1994;78(1): 64-73.
4. Brandwein MS, Jagirdar J, Patil J, Biller H, Kaneko M. Salivary duct carcinoma (cribriform salivary carcinoma of excretory ducts): a clinicopathologic and immunohistochemical study of 12 cases. Cancer. 1990;65(10): 2307-14.
5. Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD. Salivary duct carcinoma: clinicopathologic and immunohistochemical review of 26 cases. Cancer. 1996;77(2): 223-30.
6. Fan C, Melhem MF, Hosal AS, Grandis JR, Barnes EL. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor α in salivary duct carcinoma. Arch Otolaryngol. 2001;127(9): 1075-9.
7. Fan C, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 2000;24(4): 579-86.
8. Simpson RHW, Clarke TJ, Sarsfield PTL, Babajews AV. Salivary duct adenocarcinoma. Histopathology. 1991;18(3): 229-35.
9. Moriki T, Ueta S, Takahashi T, Mitani M, Ichien M. Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer Cytopathol. 2001;93(5): 344-50.
10. Hellquist HB, Karlsson MG, Nilsson C. Salivary duct carcinoma-a highly aggressive salivary gland tumour with overexpression of c-erbB-2. J Pathol. 1994;172(1): 35-44.
11. Delgado R, Vuitch F, Albores-Saavedra J. Salivary duct carcinoma. Cancer. 1993;72(5): 1503-12.
12. Williams MD, Roberts D, Blumenschein GR, et al. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol. 2007;31(11): 1645-52.
13. Simpson RHW, Prasad AR, Lewis JE, Skálová A, David L. Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol. 2003;27(8): 1070-9.
14. Barnes L, Rao U, Contis L, Krause J, Schwartz A, Scalamogna P. Salivary duct carcinoma: part II. Immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol. 1994;78(1): 74-80.
15. Felix A, El-Naggar AK, Press MF, et al. Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol. 1996;27(6): 561-6.
16. Martinez-Barba E, Cortes-Guardiola JA, Minguela-Puras A, Torroba-Caron A, Mendez-Trujillo S, Bermejo-Lopez J. Salivary duct carcinoma: clinicopathological and immunohistochemical studies. J Cranio-Maxillofac Surg. 1997;25(6): 328-34.
17. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Löning T. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer. 2005;103(12): 2526-33.
18. Etges A, Pinto DS Jr, Kowalski LP, Soares FA, Araújo VC. Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol. 2003;56(12): 914-8.
19. Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck. 2007;29(10): 907-12.
20. Cornolti G, Ungari M, Morassi ML, et al. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Arch Otolaryngol. 2007;133(10): 1031-6.
21. McHugh JB, Visscher DW, Barnes EL. Update on selected salivary gland neoplasms. Arch Pathol Lab Med. 2009;133(11): 1763-74.
22. Skálová A, Stárek I, Vanecek T, et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in situ hybridization and immunohistochemistry. Histopathology. 2003;42(4): 348-56.
23. Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res. 2010;16(8): 2266-74.
24. Sugano S, Mukai K, Tsuda H, et al. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope. 1992;102(8): 923-7.
25. Leecy T, Buckland ME, Turner J, Earls P. The use of immunohistochemistry in the diagnosis of primary salivary duct carcinoma: three case reports. Pathology. 2008;40(4): 434-7.
26. Jamal AM, Zhi-Jun S, Xin-Ming C, Yi-Fang Z. Salivary duct carcinoma of the parotid gland: case report and review of the literature. J Oral Maxillofac Surg. 2008;66(8): 1708-13.
27. Prat A, Parera M, Reyes V, et al. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck. 2008;30(5): 680-3.
28. Nashed M, Casasola RJ. Biological therapy of salivary duct carcinoma. J Laryngol Otol. 2009;123(2): 250-2.
29. Jaspers HCJ, Verbist BM, Schoffelen R, et al. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol. 2011;29(16): e473-6.
30. Krishnamurthy J, Krishnamurty DM, Baker JJ, Zhen W, Lydiatt D, Ganti AK. Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature. Head Neck. 2013;. doi: 10. 1002/hed. 23307.
31. Soper MS, Thompson LDR, Iganej S. Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy. Head Neck. 2013;. doi: 10. 1002/hed. 23383.
32. Griffith CC, Seethala RR, Luvison A, Miller M, Chiosea SI. PIK3CA mutations and PTEN loss in salivary duct carcinomas. Am J Surg Pathol. 2013;37(8): 1201-7.
33. Goode RK, El-Naggar AK. Mucoepidermoid carcinoma. In: Eveson JW, Reichart P, Sidransky D, Barnes L, editors. World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. Lyon: IARC Press; 2005. p. 219-20.
34. Goode RK, Auclair PL, Ellis GL. Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer. 1998;82(7): 1217-24.
35. Rapidis AD, Givalos N, Gakiopoulou H, et al. Mucoepidermoid carcinoma of the salivary glands: review of the literature and clinicopathological analysis of 18 patients. Oral Oncol. 2007;43(2): 130-6.
36. Guzzo M, Andreola S, Sirizzotti G, Cantu G. Mucoepidermoid carcinoma of the salivary glands: clinicopathologic review of 108 patients treated at the National Cancer Institute of Milan. Ann Surg Oncol. 2002;9(7): 688-95.
37. Kokemueller H, Brueggemann N, Swennen G, Eckardt A. Mucoepidermoid carcinoma of the salivary glands-clinical review of 42 cases. Oral Oncol. 2005;41(1): 3-10.
38. Brandwein MS, Ivanov K, Wallace DI, et al. Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am J Surg Pathol. 2001;25(7): 835-45.
39. Tonon G, Modi S, Wu L, et al. t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet. 2003;33(2): 208-13.
40. Behboudi A, Enlund F, Winnes M, et al. Molecular classification of mucoepidermoid carcinomas-prognostic significance of the MECT1-MAML2 fusion oncogene. Gene Chromosome Cancer. 2006;45(5): 470-81.
41. Chenevert J, Barnes LE, Chiosea SI. Mucoepidermoid carcinoma: a five-decade journey. Virchows Arch. 2011;458(2): 133-40.
42. Nocito A, Kononen J, Kallioniemi OP, Sauter G. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer. 2001;94(1): 1-5.
43. Hicks DG, Schiffhauer L. Standardized assessment of the HER2 status in breast cancer by immunohistochemisty. Lab Med. 2011;42(8): 459-67.
44. Di Palma S, Simpson RHW, Marchiò C, et al. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. Histopathology. 2012;61(4): 629-43.